These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16990780)

  • 1. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?
    Verstovsek S; Silver RT; Cross NC; Tefferi A
    Leukemia; 2006 Nov; 20(11):2067. PubMed ID: 16990780
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera.
    Tefferi A; Strand JJ; Lasho TL; Knudson RA; Finke CM; Gangat N; Pardanani A; Hanson CA; Ketterling RP
    Leukemia; 2007 Sep; 21(9):2074-5. PubMed ID: 17476276
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P; Hanrahan V; Baker B; Romeril K
    Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
    Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
    Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlations of JAK2V617F point mutation with clinical and laboratory features in patients with polycythemia vera].
    Shen YF; Xia J; Lu MZ; Jiang YQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):121-4. PubMed ID: 19236761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent JAK2(V617F) mutation and MTHFR(C677T) homozygosity in an adolescent with polycythemia vera: case report and discussion.
    Ehmann MR; Goodenough CJ; Lotterman CD; Warrier RP
    Clin Pediatr (Phila); 2013 Jul; 52(7):671-4. PubMed ID: 22626845
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.
    Pardanani A; Lasho TL; Finke C; Hanson CA; Tefferi A
    Leukemia; 2007 Sep; 21(9):1960-3. PubMed ID: 17597810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation screening for JAK2V617F: when to order the test and how to interpret the results.
    Tefferi A; Pardanani A
    Leuk Res; 2006 Jun; 30(6):739-44. PubMed ID: 16460800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera.
    Grünebach F; Bross-Bach U; Kanz L; Brossart P
    Leukemia; 2006 Dec; 20(12):2210-1. PubMed ID: 17008888
    [No Abstract]   [Full Text] [Related]  

  • 10. JAK2 Mutations are present in all cases of polycythemia vera.
    Wang YL; Vandris K; Jones A; Cross NC; Christos P; Adriano F; Silver RT
    Leukemia; 2008 Jun; 22(6):1289. PubMed ID: 18079740
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of molecular testing to identify a cluster of patients with polycythemia vera in eastern Pennsylvania.
    Seaman V; Jumaan A; Yanni E; Lewis B; Neyer J; Roda P; Xu M; Hoffman R
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):534-40. PubMed ID: 19190168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications.
    Tefferi A
    N Engl J Med; 2007 Feb; 356(5):444-5. PubMed ID: 17267904
    [No Abstract]   [Full Text] [Related]  

  • 13. Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera.
    Cherry M; Khawandanah M; Zhao ZJ; Srour S; Ozer H; Selby G; Ghabache B; Al-Kali A
    Ann Hematol; 2015 Apr; 94(4):717-9. PubMed ID: 25380996
    [No Abstract]   [Full Text] [Related]  

  • 14. JAK2V617F mutation in a 9-year-old girl with polycythemia vera and Budd-Chiari syndrome: a case report.
    Benedik-Dolničar M; Homan M; Brecelj J
    J Pediatr Hematol Oncol; 2012 Apr; 34(3):243-4. PubMed ID: 21552144
    [No Abstract]   [Full Text] [Related]  

  • 15. Lu/BCAM-mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients.
    De Grandis M; Cassinat B; Kiladjian JJ; Chomienne C; El Nemer W
    Am J Hematol; 2015 Jul; 90(7):E137-8. PubMed ID: 25809027
    [No Abstract]   [Full Text] [Related]  

  • 16. JAK2 exon 12 mutation in JAK2V617F-negative polycythemia vera.
    Röthlisberger B; Huber A; Bargetzi M; Mendez A; Heizmann M
    Leuk Lymphoma; 2008 Mar; 49(3):586-8. PubMed ID: 18297539
    [No Abstract]   [Full Text] [Related]  

  • 17. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients.
    Butcher CM; Hahn U; To LB; Gecz J; Wilkins EJ; Scott HS; Bardy PG; D'Andrea RJ
    Leukemia; 2008 Apr; 22(4):870-3. PubMed ID: 17914411
    [No Abstract]   [Full Text] [Related]  

  • 18. Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?
    Teofili L; Foà R; Giona F; Larocca LM
    Haematologica; 2008 Feb; 93(2):169-72. PubMed ID: 18245648
    [No Abstract]   [Full Text] [Related]  

  • 19. JAK2V617F detection and dosage of serum erythropoietin: first steps of the diagnostic work-up for patients consulting for elevated hematocrit.
    Girodon F; Lippert E; Mossuz P; Dobo I; Boiret-Dupré N; Lesesve JF; Hermouet S; Praloran V
    Haematologica; 2007 Mar; 92(3):431-2. PubMed ID: 17339201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.